Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 6/20 | 0.42 |
| ▸ | HRH1 | P35367 | 6/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742600 | 0.85 | SIGMAR1 (0.49) | SIGMAR1TLR8ACKR3 | |
| SCHEMBL1743929 | 0.83 | TLR8 (0.50) | SIGMAR1TLR8ADORA3HTR2AHTR7 | |
| SCHEMBL1743962 | 0.81 | LMNA (0.40) | HRH2HRH1ATM | |
| SCHEMBL31752794 | 0.80 | SIGMAR1 (0.56) | SIGMAR1TLR8ADORA3HTR2AHTR7 | |
| SCHEMBL1742604 | 0.78 | ACKR3 (0.51) | SIGMAR1TLR8ADORA3HTR2AHTR7 | |
| SCHEMBL1744477 | 0.78 | SIGMAR1 (0.50) | SIGMAR1TLR8ADORA3HTR2AHTR7 | |
| SCHEMBL16528206 | 0.77 | MAPK1 (0.43) | ATM | |
| SCHEMBL7971782 | 0.77 | SIGMAR1 (0.69) | SIGMAR1ADORA3HTR2AHTR7OPRM1 | |
| SCHEMBL20046103 | 0.76 | SIGMAR1 (0.52) | SIGMAR1ADORA3HTR2AHTR7OPRM1 | |
| SCHEMBL12161250 | 0.75 | SIGMAR1 (0.47) | SIGMAR1TLR8ADORA3HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981889-B1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2014-01-15 | — | — | EP | disclosed |
| US-8163736-B2 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | disclosed |
| EP-2386559-A1 | Cytotoxiv agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254808-A1 | REFLECTIVE TOUCH DISPLAY PANEL AND MANUFACTURING METHOD THEREOF | AU OPTRONICS CORPORATION (TW) | 2011-10-20 | — | — | US | disclosed |
| EP-2371827-A1 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2011-10-05 | — | — | EP | disclosed |
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| EP-1981889-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085930-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | TOMM70, TOMM34, TOMM40 | SIGMAR1 2271/4885TLR8 3231/4885ADORA3 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.